TNFRSF4 and neoplasm: Five year overall survival rate was 82% (CI: 72-94%) for patients presenting with high OX40+ and CD8+ tumor infiltration, and 48% (CI: 43-54%) for patients bearing tumors with poor OX40+ and CD8+ density (P = 0.0001).